FDA Appeal In Zocor Case Could Open The Door For More Generics In The Fall
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA filed a notice of appeal challenging a court decision granting Ivax and Ranbaxy 180-day exclusivity for generic simvastatin.
You may also be interested in...
Statin Prices Likely To Remain High After Zocor Exclusivity Win
Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.